Changes in measles serostatus among HIV-infected zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1747-1755

  Rainwater Lovett, Kaitlin ^a   Nkamba, Hope C ^b   Mubiana Mbewe, Mwangelwa ^c   Bolton Moore, Carolyn ^d,e   Moss, William J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Division of Geriatrics   (United States)

^c Centre for Infectious Disease Research   (Zambia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Antiretroviral therapy; HIV; Immune reconstitution; Measles; Outbreak

Indexed keywords

IMMUNOGLOBULIN G; MEASLES VACCINE;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MALE; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVACCINATION; SEROLOGY; SEROPREVALENCE; VIRUS IMMUNITY; ZAMBIA;

ANTIBODY; ANTIRETROVIRAL THERAPY; HIV; IMMUNE RECONSTITUTION; MEASLES; OUTBREAK;

ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE OUTBREAKS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; VIRAL LOAD; ZAMBIA;

EID: 84888601985     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit404     Document Type: Article

References (39)

1. Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23:95-106.
2. Progress toward measles control-African region, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58:1036-41.
3. Measles outbreaks and progress toward measles preelimination-African region, 2009-2010. MMWR Morb Mortal Wkly Rep 2011; 60:374-8.
4. Moss WJ, Griffin DE. Measles. Lancet 2012; 379:153-64.
5. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: The influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005; 191:1854-60.
6. Scott S, Moss WJ, Cousens S, et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007; 45:1417-24.
7. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 1992; 165:262-7.
8. World Health Organization. WHO position on measles vaccines. Vaccine 2009; 27:7219-21.
9. Lowther SA, Curriero FC, Kalish BT, Shields TM, Monze M, Moss WJ. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: A crosssectional survey. Lancet 2009; 373:1025-32.
10. Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIVinfected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis 2011; 204(suppl 1):S164-78.
11. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: An observational study. J Infect Dis 2007; 196:347-55.
12. Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virusspecific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-8.
13. Sutcliffe CG, Scott S, Mugala N, et al. Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis 2008; 47:837-44.
14. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008; 37:356-67.
15. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10:630-42.
16. Rainwater-Lovett K, Moss WJ. Immunologic basis for revaccination of HIV-infected children receiving HAART. Future Virol 2011; 6:59-71.
17. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888-99.
18. Gilliam E. Responding to a measles outbreak in Zambia. 2010. http://www.unicefusa.org/news/news-from-the-field/responding-to-a- measlesoutbreak-in-zambia.html. Accessed 21 September 2011.
19. United Nations. Funding gap leads to major measles outbreak in eastern and southern Africa. http://www.un.org/apps/news/story.asp?NewsID=35073&Cr= measles&Cr1. Accessed 21 September 2011.
20. World Health Organization. Reported measles cases and incidence rates by member states. 2012. http://www.who.int/immunization-monitoring/diseases/ measles-monthlydata/en/index1.html. Accessed 31May 2012.
21. World Health Organization. Immunological basis for immunization series, module 7: Measles, update 2009. Geneva, Switzerland: WHO, 2009.
22. World Health Organization. Child growth standards. 2011http://www.who. int/childgrowth/en/. Accessed 19 May 2010.
23. Measles Initiative. Measles in 2011: devastating, surprising outbreaks and some success. 2012. http://stopmeaslesrubella.org/2012/02/20/measles-in- 2011-devastating-and-surprising-outbreaks-and-some-success/. Accessed 4 May 2012.
24. Swihart BJ, Caffo B, James BD, Strand M, Schwartz BS, Punjabi NM. Lasagna plots: A saucy alternative to spaghetti plots. Epidemiology 2010; 21:621-5.
25. Sarkar D. Lattice: multivariate data visualization with R. New York: Springer, 2008.
26. Tools for Spatial Data. Boulder, CO: National Center for Atmospheric Research, 2006.
27. Keitt TH. Coherent ecological dynamics induced by large scale disturbance. Nature 2008; 454:331-4.
28. Rainwater-Lovett K, Moss WJ. The urgent need for recommendations on revaccination of HIV-infected children after successful antiretroviral therapy. Clin Infect Dis 2010; 51:634-5.
29. Maldonado Y. Measles vaccine, HIV infection, and antiretroviral therapy-a window of opportunity. J Infect Dis 2012; 206:466-8.
30. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- And post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-9.
31. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006; 7:467-70.
32. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4.
33. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-4.
34. Abzug MJ, Qin M, Levin MJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2012; 206:512-22.
35. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-42.
36. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
37. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De SG. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172: 1591-5.
38. Good RA, Zak SJ. Disturbances in gamma globulin synthesis as experiments of nature: E. Mead Johnson Award. Pediatrics 1956; 18: 109-49.
39. Markowitz LE, Chandler FW, Roldan EO, et al. Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis 1988; 158:480-3.